Vitamin D Supplement
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Patient Adherence
Conditions
Patient Adherence
Trial Timeline
Dec 15, 2014 → Jul 11, 2018
NCT ID
NCT02367599About Vitamin D Supplement
Vitamin D Supplement is a approved stage product being developed by Gilead Sciences for Patient Adherence. The current trial status is completed. This product is registered under clinical trial identifier NCT02367599. Target conditions include Patient Adherence.
What happened to similar drugs?
20 of 20 similar drugs in Patient Adherence were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02367599 | Approved | Completed |
Competing Products
20 competing products in Patient Adherence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 32 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| ASP8825 | Astellas Pharma | Phase 1 | 29 |
| ASP015K | Astellas Pharma | Phase 1 | 29 |
| ASP7991 | Astellas Pharma | Phase 1 | 29 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 40 |
| ATG-F | Astellas Pharma | Approved | 43 |
| Celecoxib | Astellas Pharma | Pre-clinical | 26 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| FK949E | Astellas Pharma | Phase 1 | 29 |